In vivo hepatic HB-EGF gene transduction inhibits Fas-induced liver injury and induces liver regeneration in mice: a comparative study to HGF
NC Khai, T Takahashi, H Ushikoshi, S Nagano… - Journal of …, 2006 - Elsevier
BACKGROUND/AIMS: It is unknown whether heparin-binding EGF-like growth factor (HB-
EGF) can be a therapeutic agent, although previous studies suggested that HB-EGF might
be a hepatotrophic factor. This study explores the potential of hepatic HB-EGF gene therapy
in comparison with HGF. METHODS: Mice received an intraperitoneal injection of the
agonistic anti-Fas antibody 72h after an intravenous injection of either adenoviral vector (1×
1011 particles) expressing human HB-EGF (Ad. HB-EGF), human HGF (Ad. HGF) or no …
EGF) can be a therapeutic agent, although previous studies suggested that HB-EGF might
be a hepatotrophic factor. This study explores the potential of hepatic HB-EGF gene therapy
in comparison with HGF. METHODS: Mice received an intraperitoneal injection of the
agonistic anti-Fas antibody 72h after an intravenous injection of either adenoviral vector (1×
1011 particles) expressing human HB-EGF (Ad. HB-EGF), human HGF (Ad. HGF) or no …